27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our findings indicate that all methods captured AD disconnection patterns but exhibited variability in preserving connectivity profiles, which seemed non-random but rather systematically linked to clinical measures and predictive power for AD classification. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this cross-sectional sample, mobility showed a progressively stronger statistical indirect association with the cognition-ADL relationship as cognitive impairment deepened. 3 key findings →
Design: cross-sectional Participants: 1,234 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These findings identify an anatomically specific age-related profile of the human BF, with structural vulnerability manifest and pre-diagnostic neurological disorders, which is not substantially explained by common inherited risk. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
GCC countries are experiencing a rapid demographic transition. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In older adults with HFpEF, finerenone conferred renal benefit without a detectable short-term cognitive signal. 3 key findings →
Design: cohort study Participants: 1,660 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neurodegenerative diseases posit a global challenge due to their aging-dependent increasing incidence around the world. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Between 1979 and 2023, AD caused 2,430,795 deaths in U.S. adults. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder, and its incidence is rising rapidly with population aging. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Rare confirmed initiation prevented a clinically interpretable admission-time strategy estimate. 3 key findings →
Participants: 3,706 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Digital literacy is a meaningful predictor of HRQoL in older adults with intact or mildly impaired cognition, underscoring its potential as an intervention target in digital health strategies. 5 key findings →
Design: cross-sectional Participants: 121 Evidence: low
Full summary, score breakdown and related studies → Original source
Neuroexposome research investigates associations between physical, chemical, biological, and psychosocial factors and neurological health. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Consequently, changes in mitochondrial DNA copy number (mtDNA-CN), the number of mtDNA genomes per cell or tissue sample, are associated with diseases ranging from cancer and obesity to psoriasis and all-cause mortality. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
The Klotho (KL) gene encodes a single-pass transmembrane protein that functions as a potent suppressor of aging. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
While the widespread adoption of electronic medical records (EMRs) has significantly improved healthcare efficiency and resource allocation, the sensitivity of medical data poses serious privacy breach risks. 2 key findings →
Participants: 1,235,651 Evidence: low
Full summary, score breakdown and related studies → Original source
The dynamics of Alzheimer’s disease spread in aging groups of population are described using an Inflow-Outflow Model. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The MoE-derived DNN-IR index demonstrated robust and stable performance in predicting atherosclerosis, incident CVD, cardiovascular mortality, and all-cause mortality in the general population. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
These estimates are planning values for populations resembling the contributing studies, not national population rates. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
DNA cytosine modifications play a crucial role in gene regulation that underlies the pathogenesis of complex diseases such as Alzheimer’s disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Longitudinal clinical cohorts contain heterogeneous progression patterns that are obscured by coarse diagnostic labels. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Retirement timing alone showed limited association with later-life dementia risk, whereas sustained part-time employment and disability-related trajectories were more strongly associated with dementia risk. 5 key findings →
Participants: 13,879 Evidence: low
Full summary, score breakdown and related studies → Original source
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) provides a comprehensive multimodal neuroimaging resource for studying aging and Alzheimer’s disease (AD). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Brain aging reflects heterogeneous vascular-metabolic and neurodegenerative processes, yet brain age is often reduced to a gray matter (GM)-dominant estimate. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease classification by means of Magnetic Resonance Imaging demands strong models that are able to generalise to different stages of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sensitive human data underpin discoveries across medicine, biology and the social sciences, yet privacy regulation often prevents sharing them with collaborators or artificial intelligence (AI) systems. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Risk prediction in Alzheimer disease can guide follow-up, biomarker testing, trial referral, and prognostic counseling. 1 key finding →
Participants: 1,002 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →